Prescribing guide
Epidiolex (cannabidiol)Weight-based dosing, liver test schedule, drug interactions and prior authorization criteria for Dravet syndromeFor prescribers and their offices treating dravet syndrome: what the pharmacy needs before it ships, what the prior authorization wants documented, the titration and the monitoring the label requires.
Dispensing gate
No REMS: baseline ALT, AST and total bilirubin, then prior authorization and a specialty pharmacy that works with the plan.
Example PA threshold
Cigna example: age 1 or older, neurologist, at least 2 other ASMs or one of Fintepla, Diacomit or clobazam tried or concomitant, 1-year approval.
Monitoring
ALT, AST and total bilirubin at baseline, 1, 3 and 6 months, then periodically and within 1 month of dose or interacting-drug changes; somnolence; weight; mood and suicidality.
Support line
JazzCares: 1-833-426-4243, weekdays 8 AM to 8 PM ET; copay as little as $0 for commercial plans with no enrollment needed; Nurse Navigator.
Give your patient their plan
A one-page handout for starting Epidiolex, in plain language: what the first fill waits on, the first dates, who will call and the symptoms to report, with blank lines for the start date and your office's number. The link opens the patient's full first 90 days page, where their dates become calendar entries.
trialfriend.com/p/epidiolexBefore the first fill: REMS, labs and enrollment
The steps that the pharmacy, the REMS or the drugmaker's program will wait on, in the order they usually need to happen. A first fill of a specialty drug most often stalls on one of these rather than on the plan.
| Step | What it requires | Source |
|---|---|---|
| Baseline labs | Obtain ALT, AST and total bilirubin in all patients before starting. With transaminases above 3 times ULN and bilirubin above 2 times ULN at baseline, evaluate before initiating. | FDA label |
| Specialty pharmacy | Jazz routes the prescription to a specialty pharmacy that works with the patient's insurance; the pharmacy calls the family to confirm coverage and ships to the home. | How to get Epidiolex |
| Copay program | No enrollment; the pharmacy assesses eligibility during the benefit investigation and applies the JazzCares copay benefit automatically for eligible commercially insured patients. | Copay program |
| Supply | 100mg/mL in 60mL or 100mL bottles; each carton has two 1mL and two 5mL oral syringes and adapters. Discard 12 weeks after first opening. | FDA label |
Prior authorization criteria and what to document
One public policy as the example: Cigna, May 1, 2026. Approval approved a year at a time. Renewal needs the patient to be responding, such as reduced seizure severity, frequency or duration, as judged by the prescriber. This version took effect May 1, 2026 and cites the June 2025 label, before the June 2026 revision, which did not change dosing or the Dravet indication. Other plans set their own criteria and approval lengths. It is here as an example of what a plan asks for, not as a rule.
| Element | What the policy asks | In the chart | Source |
|---|---|---|---|
| Age | 1 year or older | Date of birth on the request | Cigna policy |
| Diagnosis | Seizures associated with Dravet syndrome | Neurology note with the diagnosis | Cigna policy |
| Prior or concomitant ASMs | At least 2 other antiseizure medications (examples: valproic acid, topiramate, clonazepam, levetiracetam, zonisamide), or one of Fintepla, Diacomit or clobazam | Medication history or current list with dates | Cigna policy |
| Prescriber | Prescribed by or in consultation with a neurologist | Specialty on the request, or the consult note | Cigna policy |
| Continuation | Responding to therapy, such as reduced seizure severity, frequency or duration, as determined by the prescriber; approval 1 year | Seizure diary or progress note | Cigna policy |
Epidiolex dosing and titration
| When | Label | Source |
|---|---|---|
| Start | 2.5mg/kg twice daily (5mg/kg/day). | FDA label |
| After 1 week | May increase to the maintenance dose of 5mg/kg twice daily (10mg/kg/day). | FDA label |
| Further titration | Weekly increments of 2.5mg/kg twice daily to a maximum of 10mg/kg twice daily (20mg/kg/day); no more often than every other day if faster titration is warranted. 20mg/kg/day gave somewhat greater seizure reduction with more adverse reactions. | FDA label |
| Food | Dose consistently with respect to meals; a high-fat meal raised Cmax about 5-fold and AUC about 4-fold. | FDA label |
| Enteral tubes | Silicone nasogastric or gastrostomy tubes, flushing with about 5 times the priming volume; not PVC or polyurethane tubes, and avoid silicone NG tubes under 50cm and under 5 FR. | FDA label |
| Hepatic impairment | Dose adjustment recommended for moderate or severe hepatic impairment (section 2.6). | FDA label |
| Discontinuation | Decrease gradually to minimize increased seizure frequency and status epilepticus. | FDA label |
Monitoring the Epidiolex label requires
| When | What | What the label says to do with it | Source |
|---|---|---|---|
| Baseline | ALT, AST, total bilirubin | All patients before starting | FDA label |
| 1, 3 and 6 months | ALT, AST, total bilirubin | Then periodically or as clinically indicated; elevations typically in the first 2 months, some up to 18 months, especially with valproate | FDA label |
| Dose or drug changes | ALT, AST, total bilirubin | Within 1 month of an Epidiolex dose change or adding or changing medicines that affect the liver | FDA label |
| Stopping rule | Transaminases | Discontinue if above 3 times ULN with bilirubin above 2 times ULN, or sustained above 5 times ULN | FDA label |
| Throughout | Somnolence and sedation | 32% against 11% on placebo in LGS and DS; 46% with clobazam against 16% without | FDA label |
| Throughout | Weight, mood, suicidality | Weight loss of at least 5% in 16% against 8%; monitor for suicidal behavior and thoughts | FDA label |
| Labs to interpret | Hemoglobin and creatinine | New anemia more often than placebo; creatinine rises about 10% within 2 weeks, not due to reduced GFR | FDA label |
Epidiolex drug interactions and contraindications
| Label category | Agents and what the label says | Source |
|---|---|---|
| Valproate | More transaminase elevations; consider discontinuing or reducing Epidiolex and/or valproate if elevations occur. | FDA label |
| Clobazam | N-desmethylclobazam about 3-fold higher; more somnolence and pneumonia. Consider reducing clobazam if its adverse reactions appear. | FDA label |
| Strong CYP3A4 or CYP2C19 inducers | Rifampin lowered cannabidiol about 32% and 7-OH-CBD about 63%; consider an Epidiolex dose increase. | FDA label |
| Everolimus | A lower starting dose of oral everolimus is recommended. | FDA label |
| CYP2C19 substrates | Consider dose reduction; for prodrugs such as clopidogrel, Epidiolex may lower the active metabolite and efficacy. | FDA label |
| CYP1A2, CYP2C8, UGT1A9 and oral P-gp substrates; CYP2B6 | Consider dose reduction of sensitive substrates; consider modifying CYP2B6 substrate doses. | FDA label |
| CNS depressants and alcohol | Increased somnolence and sedation. | FDA label |
| Drug screens | Counsel that positive cannabis drug screens are possible. | FDA label |
Why a first fill stalls, and the fix
- Prior authorization pending or deniedCigna asks for age 1 or older and a neurologist. It also wants 2 other seizure medicines, or one of Fintepla, Diacomit or clobazam, tried or taken alongside. The office lists those medicines on the request. Cigna approves 1 year at a time.
- A copay you cannot payWith commercial insurance, eligible patients may pay as little as $0 per prescription through the JazzCares Copay Savings Program, with possible monthly or annual limits. It is not valid with Medicare, Medicaid or other government programs. Our help paying page lists charity funds.
- The pharmacy cannot reach youJazz says to answer calls from unfamiliar 1-800 or local numbers, because the specialty pharmacy calls to confirm insurance and delivery before shipping.
JazzCares (Jazz Pharmaceuticals)
- JazzCares Copay Savings Program for commercial insurance, as little as $0 per prescription, with possible monthly or annual limits. No enrollment needed, since the pharmacy checks eligibility. Not valid with Medicare, Medicaid, VA, TRICARE, the Indian Health Service or other government programs Copay program
- A JazzCares Nurse Navigator for information and questions during treatment How to get Epidiolex
- Delivery from a specialty pharmacy that works with the family's insurance, with some able to ship to a local store for pickup How to get Epidiolex
Questions prescribers' offices ask about Epidiolex
What is the Epidiolex dose in Dravet syndrome?
2.5mg/kg twice daily to start, then 5mg/kg twice daily after one week, per the May 2026 label (section 2.2). Patients tolerating 5mg/kg twice daily who need more seizure reduction may increase weekly by 2.5mg/kg twice daily to a maximum of 10mg/kg twice daily, or no more often than every other day if faster titration is warranted.
What liver monitoring does the Epidiolex label require?
ALT, AST and total bilirubin before starting, then at 1, 3 and 6 months and periodically thereafter, per the May 2026 label (sections 2.1 and 5.1). Also test within 1 month of a dose change or of adding or changing medicines that affect the liver, and consider more frequent testing with valproate or elevated baseline enzymes. Discontinue for transaminases above 3 times ULN with bilirubin above 2 times ULN, or sustained above 5 times ULN.
How do valproate and clobazam change the risk?
In the LGS and DS trials, ALT above 3 times ULN occurred in 30% with valproate and clobazam, 21% with valproate alone, 4% with clobazam alone and 3% with neither, per the May 2026 label (section 5.1). Epidiolex raises the clobazam metabolite N-desmethylclobazam about 3-fold; consider a clobazam dose reduction for clobazam adverse reactions.
Does Epidiolex have a REMS or boxed warning?
No, per the May 2026 label. It is not a controlled substance. Warnings cover hepatocellular injury, somnolence and sedation, suicidal behavior and ideation, hypersensitivity, and gradual withdrawal.
What do insurers ask for to approve Epidiolex in Dravet syndrome?
The Cigna policy shown here, IP0410 effective May 1, 2026, asks for age 1 or older, a neurologist, and a trial or concomitant use of at least 2 other antiseizure medications or one of Fintepla, Diacomit or clobazam. Approval is for 1 year, and continuation requires response as determined by the prescriber. The policy cites the June 2025 label.
Free email alert
Get an email when the Epidiolex label changes
One email the day the FDA revises the Epidiolex prescribing information, with a summary of what changed. No trial alerts or newsletter, and you can stop anytime.
Label changes for Epidiolex only, usually a few a year and some years none. Stop anytime. We never share your email. Privacy policy
Sources
- EPIDIOLEX (cannabidiol) oral solution: prescribing information, Medication Guide and Instructions for Use, Jazz Pharmaceuticals, Inc., via DailyMed, 2026-05-29.
- The EPIDIOLEX® Copay Savings Program, Jazz Pharmaceuticals, 2026-11-10.
- Doctor Discussions and Financial Support | EPIDIOLEX® (cannabidiol), Jazz Pharmaceuticals, 2026-11-10.
- Drug Coverage Policy IP0410, Epidiolex (Antiseizure Medications, Epidiolex), Cigna, 2026-05-01.
- Drugs@FDA record for NDA 210365, EPIDIOLEX, via openFDA, FDA, 2026-11-10.
A reference drawn from the May 29, 2026 label, the drugmaker's published program and one public insurer policy shown as an example, checked on November 10, 2026. Labels and policies change; the label on DailyMed and the plan's current policy govern. Trial Friend is not a medical provider. It reports what these documents say and does not judge whether a drug is safe or right for any patient; that is the prescriber's decision. Not a substitute for the prescribing information.